J&J Slashes 2026 Profit Outlook by $0.64 on Deal Costs, Warns of Bigger 2027 Hit
JNJ sits 59% above its 52-week low of $164.23.
Summary
J&J cut its 2026 adjusted EPS guidance to $10.96-$11.11 from $11.60-$11.75, a $0.64 reduction driven by the Firefly Bio acquisition ($0.46) and Sail Biomedicines collaboration ($0.18). Revenue guidance was maintained at $100.8B-$101.4B. The company also flagged a larger $1.36 EPS impact in 2027, mostly from Sail milestones and option exercise. J&J has completed the acquisition of Firefly Bio, Inc. to advance next-generation oncology innovation, and has come to a strategic agreement with Sail Biomedicines. Shares fell 1.4% after hours.
At the time of this announcement, JNJ was trading at $261.39 on NYSE in the Life Sciences sector, with a market capitalization of approximately $639.9B. The 52-week trading range was $164.23 to $274.90. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.